Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Lung Adenocarcinoma-Pipeline Review, H1 2015

Lung Adenocarcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Lung Adenocarcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Lung Adenocarcinoma-Pipeline Review, H1 2015', provides an overview of the Lung Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Lung Adenocarcinoma Overview 9

Therapeutics Development 10

Pipeline Products for Lung Adenocarcinoma-Overview 10

Pipeline Products for Lung Adenocarcinoma-Comparative Analysis 11

Lung Adenocarcinoma-Therapeutics under Development by Companies 12

Lung Adenocarcinoma-Therapeutics under Investigation by Universities/Institutes 14

Lung Adenocarcinoma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Lung Adenocarcinoma-Products under Development by Companies 18

Lung Adenocarcinoma-Products under Investigation by Universities/Institutes 20

Lung Adenocarcinoma-Companies Involved in Therapeutics Development 21

Amgen Inc. 21

Astex Pharmaceuticals, Inc. 22

AstraZeneca PLC 23

AVEO Pharmaceuticals, Inc. 24

Axelar AB 25

Bayer AG 26

BioNumerik Pharmaceuticals, Inc. 27

Boehringer Ingelheim GmbH 28

DiNonA Inc. 29

Eisai Co., Ltd. 30

Genentech, Inc. 31

Genmab A/S 32

Immunomedics, Inc. 33

Incyte Corporation 34

Medisyn Technologies, Inc. 35

Pfizer Inc. 36

Sanofi 37

VG Life Sciences, Inc. 38

Vichem Chemie Research Ltd. 39

Lung Adenocarcinoma-Therapeutics Assessment 40

Assessment by Monotherapy Products 40

Assessment by Combination Products 41

Assessment by Target 42

Assessment by Mechanism of Action 45

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

4-B4-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

afatinib-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AV-203-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AXL-1717-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AZD-6738-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

BAY-1163877-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

dacomitinib-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

DBPR-112-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

dimesna-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

hydroxychloroquine + sorafenib tosylate-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Interferon Lambda-1 Linked Fab Dimer-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

lenvatinib-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

MAG-Tn3-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

MT-477-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

ruxolitinib phosphate-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

SAR-408701-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecule for Cancer-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecule to Inhibit EGFR for Oncology-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules to Activate PKM2 for Lung Adenocarcinoma-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

SNX-5422-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

solitomab-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Stem Cell Therapy for Oncology-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

TdCyd-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

TF-011 Monomethyl Auristatin E-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Vaccine for Lung Adenocarcinoma-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Lung Adenocarcinoma-Recent Pipeline Updates 93

Lung Adenocarcinoma-Dormant Projects 118

Appendix 119

Methodology 119

Coverage 119

Secondary Research 119

Primary Research 119

Expert Panel Validation 119

Contact Us 119

Disclaimer 120

List of Tables

Number of Products under Development for Lung Adenocarcinoma, H1 2015 10

Number of Products under Development for Lung Adenocarcinoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

Lung Adenocarcinoma-Pipeline by Amgen Inc., H1 2015 21

Lung Adenocarcinoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 22

Lung Adenocarcinoma-Pipeline by AstraZeneca PLC, H1 2015 23

Lung Adenocarcinoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 24

Lung Adenocarcinoma-Pipeline by Axelar AB, H1 2015 25

Lung Adenocarcinoma-Pipeline by Bayer AG, H1 2015 26

Lung Adenocarcinoma-Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 27

Lung Adenocarcinoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 28

Lung Adenocarcinoma-Pipeline by DiNonA Inc., H1 2015 29

Lung Adenocarcinoma-Pipeline by Eisai Co., Ltd., H1 2015 30

Lung Adenocarcinoma-Pipeline by Genentech, Inc., H1 2015 31

Lung Adenocarcinoma-Pipeline by Genmab A/S, H1 2015 32

Lung Adenocarcinoma-Pipeline by Immunomedics, Inc., H1 2015 33

Lung Adenocarcinoma-Pipeline by Incyte Corporation, H1 2015 34

Lung Adenocarcinoma-Pipeline by Medisyn Technologies, Inc., H1 2015 35

Lung Adenocarcinoma-Pipeline by Pfizer Inc., H1 2015 36

Lung Adenocarcinoma-Pipeline by Sanofi, H1 2015 37

Lung Adenocarcinoma-Pipeline by VG Life Sciences, Inc., H1 2015 38

Lung Adenocarcinoma-Pipeline by Vichem Chemie Research Ltd., H1 2015 39

Assessment by Monotherapy Products, H1 2015 40

Assessment by Combination Products, H1 2015 41

Number of Products by Stage and Target, H1 2015 43

Number of Products by Stage and Mechanism of Action, H1 2015 46

Number of Products by Stage and Route of Administration, H1 2015 49

Number of Products by Stage and Molecule Type, H1 2015 51

Lung Adenocarcinoma Therapeutics-Recent Pipeline Updates, H1 2015 93

Lung Adenocarcinoma-Dormant Projects, H1 2015 118

List of Figures

Number of Products under Development for Lung Adenocarcinoma, H1 2015 10

Number of Products under Development for Lung Adenocarcinoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 40

Number of Products by Top 10 Targets, H1 2015 42

Number of Products by Stage and Top 10 Targets, H1 2015 42

Number of Products by Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 45

Number of Products by Top 10 Routes of Administration, H1 2015 48

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 49

Number of Products by Top 10 Molecule Types, H1 2015 50

Number of Products by Stage and Top 10 Molecule Types, H1 2015 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

AVEO Pharmaceuticals, Inc.

Axelar AB

Bayer AG

BioNumerik Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

DiNonA Inc.

Eisai Co., Ltd.

Genentech, Inc.

Genmab A/S

Immunomedics, Inc.

Incyte Corporation

Medisyn Technologies, Inc.

Pfizer Inc.

Sanofi

VG Life Sciences, Inc.

Vichem Chemie Research Ltd.

Lung Adenocarcinoma Therapeutic Products under Development, Key Players in Lung Adenocarcinoma Therapeutics, Lung Adenocarcinoma Pipeline Overview, Lung Adenocarcinoma Pipeline, Lung Adenocarcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com